GID BIO Blog
Read Updates from GID BIO.
GID BIO welcomes business titan, Roy J. Bostock as new board chair
Our team announced that Roy J. Bostock, a global business leader with decades of experience, has been elected as the
Physicians: advancing the future of evidence-based cellular therapy could increase quality of life for 14 million US adults suffering from knee osteoarthritis
Over the past three decades cardiothoracic procedures have significantly shifted to minimally invasive techniques with new technology, training of physicians
Leaders come together for the first time to advance the field of cellular therapy and its treatment of pain and function associated with knee osteoarthritis
A first-of-its kind meeting brought leaders from eight orthopedic, sports medicine, pain management and regenerative medicine advocacy organizations together to
Device and cellular therapy could lead to a major development in the treatment of pain and function associated with knee osteoarthritis for 14 million US adults
Individuals who overuse their joints, such as athletes, military members and people working physically demanding jobs are at a high
GID BIO aims to make treatment for pain and function associated with knee osteoarthritis accessible to millions with a single-use device and point-of-care therapy
Osteoarthritis (OA) of the knee is a painful disease that impacts 14 million U.S. adults. With no surgical or pharmaceutical treatment
Precision medicine could improve treatment for 14 million U.S. adults with knee osteoarthritis
Precision medicine — commonly referred to as personalized medicine — is widely recognized as the future of U.S. healthcare.
American Journal of Sports Medicine to publish results of an FDA-approved clinical trial
Trial measures safety and efficacy of device and point-of-care therapy; first to meet endpoints for reducing pain and improving function
Device and point-of-care therapy intended to treat pain and function could soon help knee osteoarthritis patients
About 30 million U.S. adults suffer from osteoarthritis (OA). Many of these patients put up with pain in the hopes of
FDA-approved trial for cellular implant therapy could mean a major development in the treatment of pain associated with knee osteoarthritis
A randomized controlled Phase IIb clinical trial approved by the Food and Drug Administration (FDA) measuring safety and efficacy of our single-use SVF-2 device
